ASH Agenda for Hematology Research
The ASH Agenda for Hematology Research serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries. Learn more.
Enhancing precision medicine efforts in hematology will require that sequencing technologies be adopted in drug discovery efforts, and in the assessment of disease predisposition, and response to therapy. In addition, appropriate infrastructure must be developed to integrate genomic and epigenomic medicine into the clinic.
Next-generation clinical studies will address important questions about emerging immunologic therapies but require an improved understanding of the basic biology of the immune system, including adaptive immunity, innate immunity, adjuvants, and tumor immune-surveillance.
While genome editing technology represents a highly promising area to advance the future of therapy for hematologic disorders, critical questions must be addressed to effectively translate this approach into clinical use.
New insights and technologies have the potential to optimize the use of stem cells and regenerative medicine, creating "designer" cells that will redefine approaches to the diagnosis and treatment of hematologic diseases.
Research on epigenetics, including its mechanisms and drivers, will elucidate highly valuable targets and lead to potentially transformative treatment regimens for hematologic disorders.
To improve upon the state of care for VTE, future research must aim to understand pathophysiologic mechanisms that lead to VTE in different patient populations as well as address unanswered questions about disease risk profiles, and the role of antithrombotics for VTE prevention in different clinical situations.
This living document, created in response to the emergence of hematologic complications from COVID-19 infection, includes research questions related to coagulation and thrombosis, vulnerable populations and health disparities, hematologic malignancies, hematopoiesis and hematopoietic dysfunction, inflammatory signaling and cytokine release, and transfusion medicine and convalescent plasma.
Looking to the future, these areas represent some of the most promising strategies to overcome the limitations of current therapies and accelerate momentum to cure hematologic diseases. Dedicated research funds will enable the pursuit of these compelling opportunities and will equip the next generation of scientists in the field to produce high-impact results and ultimately introduce new standards of care that will not only transform the diagnosis and treatment of patients with hematologic diseases today, but will form the basis for continued scientific progress in hematology and other fields of medicine for years to come.
The Agenda for Hematology Research is developed by ASH’s Committee on Scientific Affairs with extensive input from the Society’s 18 scientific committees, ASH Executive Committee and individual members. ASH thanks all members who contributed to this effort.
For more information about the ASH Agenda for Hematology Research, contact the ASH Scientific Affairs Manager, Alice Kuaban, MS, at email@example.com.